News

ATR Founder Masha Fridkis-Hareli was an instructor at the training seminar Immunology for Drug Discovery Scientists as part of PEGS held on April 8 - 12, 2019 in Boston, MA. For more information, refer to the following link: https://www.pegsummit.com/Training-Seminars/ts10b-detailed-agenda

ATR Founder Masha Fridkis-Hareli was an instructor at the training seminar Immunology for Drug Discovery Scientists as part of the Immuno-Oncology Summit held on August 27 - September 31, 2018 in Boston, MA. For more information, refer to the following link: https://www.immuno-oncologysummit.com/Immunology-Drug-Discovery/

ATR Founder Masha Fridkis-Hareli co-authored a review titled Peptide-Based Immunotherapeutics and Vaccines 2017 published in Journal of Immunology Research 2018: 4568239. Full text can be found here:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079504/ 

ATR Founder Masha Fridkis-Hareli was an instructor at the training seminar Immunology for Drug Discovery Scientists as part of PEGS held on April 30 - May 4, 2018 in Boston, MA. For more information, refer to the following link: https://www.pegsummit.com/uploadedFiles/PEGS/Agenda/18/PEGS-Boston-Brochure-2018.pdf

ATR Founder Masha Fridkis-Hareli was an instructor at the training seminar Immunology for Drug Discovery Scientists as part of the Immuno-Oncology Summit held on August 28 - September 1, 2017 in Boston, MA. For more information, refer to the following link: http://www.giiconference.com/chi422804/seminar.shtml

ATR Founder Masha Fridkis-Hareli organized a Mass Bio forum titled: Demystifying Generic Drug Development - Obstacles & Solutions. This forum discussed the processes of generic drug development from early stages all the way to market launch by exploring 1) What it takes to develop generic drugs; 2) What is a successful platform for cost effective generic competition; 3) Challenges and how companies address them (including R&D challenges and manufacturing issues); 4) Driving factors behind IP decisions; and 5) Lessons learned that can be applied throughout industry. Live-stream of this forum can be found here:​​​​http://www.ustream.tv/recorded/84870377 

ATR Founder Masha Fridkis-Hareli was featured in the Nature Magazine in the article on quality control of science in academia. For the full text see here: http://www.nature.com/news/how-quality-control-could-save-your-science-1.19223

ATR Founder Masha Fridkis-Hareli co-authored an abstract titled PrecilinicalEvaluation of RA101495, a Potent Cyclic Peptide Inhibitor of C5 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria, presented at the ASH Annual Meeting. For this work, ATR contributed its expertise in complement assay design and implementation. Full text can be found here: http://www.bloodjournal.org/content/126/23/939.full.pdf

ATR Founder Masha Fridkis-Hareli co-authored an Editorial and served as Guest Editor for a Special Issue on Peptide-Based Immunotherapeutics and Vaccines of the Journal of Immunology Research. Full text can be found here: http://www.hindawi.com/journals/jir/2015/349049/

ATR Founder Masha Fridkis-Hareli authored a chapter titled Immune Responses to CMV and Vaccine Development in: Vaccines for Latent Viral Infections by Lilijana Stevceva, Bentham Science Publishers. For more information see here: http://ebooks.benthamscience.com/book/9781681081328/chapter/135517/

ATR Founder Masha Fridkis-Hareli organized a two-part Mass Bio forum titled: Overcoming Challenges in Rare Disease Research Part I: Will Innovation & Technology "Bridge" the Gaps in Translational Medicine for Orphan Diseases? This forum discussed challenges in the development of preclinical models for orphan diseases and addressed a number of questions related to how new technologies are being leveraged to facilitate target identification and led optimization; what are the risks associated with these new paths towards clinical development; what are the challenges from a regulatory and clinical design perspective as we bring new technologies into clinical development, and are there ways to de-risk innovative treatments more quickly in the orphan disease space? For more information: http://www.massbio.org/events/calendar/3247-overcoming_challenges_in_rare_disease_research/event_detail

ATR Founder Masha Fridkis-Hareli participated as a panelist in the Naturejobs Career EXPO. The NaturejobsCareer Expo 2015, hosted for the second time in Boston, United States, offers young, talented researchers an excellent opportunity to meet a diverse selection of national and international employers from academic institutions and scientific industries, such as pharmaceutical organizations, digital technology companies, science publishing and more. For more information see: https://twitter.com/MASSAWIS/status/601107662223310848

http://www.nature.com/naturejobs/career-expo/event/naturejobs-career-expo-boston/

ATR Founder Masha Fridkis-Hareli participated as a panelist in the MassBioSciencesCareer Development Workshop held at the Broad Institute in Cambridge, MA. Organized by the Postdoctoral Associations at Boston Children's Hospital, Harvard School of Public Health, Tufts University, Dana-Farber Cancer and Broad Institute, this workshop aimed at bringing area scientists together for a two-day training event where they learned about transferable skills, leadership and management styles, alternative career paths and networking techniques. For more information see: http://biocareerworkshop.com/

ATR Founder Masha Fridkis-Hareli has been invited by the Office of Professional Development at the University of Massachusetts Amherst to present two career development workshops on academia-industry transition for the international students. For more information see: https://www.umass.edu/gradschool/office-of-professional-development?utm_source=opd_events&utm_medium=email&utm_content=email_link_intro&utm_campaign=opd_newsletter_9-8-14#Career

ATR Founder Masha Fridkis-Hareli organized and moderated a Mass Bio forum titled: MassConnect Companies Present: Spotlight on Science. MassCONNECT is MassBio'sprogram that connects entrepreneurs and founders with seasoned life sciences professionals to catalyze and commercialize innovation. Each year 12 emerging companies graduate from the MassCONNECT program. For more information see: http://www.massbio.org/events/calendar/2815-massconnect_companies_present_spotlight_on/event_detail

ATR Founder Masha Fridkis-Hareli moderated a Mass Bio forum titled New Funding Opportunities from the National Institute for Neurological Diseases and Stroke. The Office of Translational Research (OTR) at the National Institutes for Neurological Disorders and Stroke (NINDS) has launched a new suite of non-dilutive funding programs to support academic investigators and small businesses to engage in therapeutic and device discovery and development in neurological disorders. This support begins with assay development through to initial test of clinical candidate in human trials. For more information see below: http://www.massbio.org/events/calendar/2793-new_funding_opportunities_from_the_national/event_detail

ATR Founder Masha Fridkis-Hareli participated as a panelist in the seminar titled: Science Shaping Our World-SHOW: Life Science Trending Around the Globe-Making Local Innovations Go Global. Science Shaping Our World-SHOW is an ongoing seminar and networking series that highlights cutting edge translational life science research and development. SHOW's mission is to provide a stage for researchers that are at the cutting edge of life science innovation and translation whereby they can share their work and discuss its future application potential in a non-conventional setting. For more information see below: 

http://www.eventbrite.com/e/science-shaping-our-world-showlife-science-trending-around-the-globe-making-local-innovations-go-registration-11582975993

ATR Founder Masha Fridkis-Hareli exhibited at the Seventh Massachusetts Life Sciences Innovation Day (MALSI) held at the Harvard Club in Boston, MA. MALSI Day is the biggest day for life sciences startups and innovation in the Commonwealth of Massachusetts. This is a high-energy, hands-on event which brings together scientific leaders and business experts to mingle with scientists, post-docs, professors, entrepreneurs, innovators, and venture capitalists. For more information see below: http://media.umassp.edu/mattcenter/malsi-day-2014/MALSID%202014_Notebook.pdf

ATR Founder Masha Fridkis-Hareli participated as a panelist in the STEM Career Exploration Day organized by the Graduate Women In Science and the Office of Professional Development at the University of Massachusetts Amherst. For more information see below: http://blogs.umass.edu/gwis/initiatives-and-programs/professional-development/bio-of-dr-masha-hareli/

ATR Founder Masha Fridkis-Hareli participated as a panelist and exhibitor in the CRO/CMO3rd Annual Accelerating Drug Development Symposium held in Burlington, MA. The Massachusetts CRO/CMO Symposium shines a spotlight on the strength and success of the CRO and CMO communities in the Commonwealth. The Symposium draws more than 300 attendees to discuss and evaluate the best alternatives that have evolved in shortening time to market. A series of case studies, interactive panel discussions, and networking sessions provide ample time to explore the various techniques and approaches being used by both virtual and established companies. For more information see below: http://www.massbio.org/events/calendar/2303-massachusetts_cro_cmo_symposium/event_detail/545http://www.massbio.org/events/calendar/2303-massachusetts_cro_cmo_symposium/event_detail/539

ATR Founder Masha Fridkis-Hareli organized and moderated a Mass Bio forum titled: From Academia to Industry Part II: Using Animal Models in Pre-Clinical Drug Development. This is the second Forum in the series where academic investigators discuss applications of their research animal models for collaborative initiatives with biotechnology industry that could accelerate the translation of early stage candidates into drug discovery and development programs. For more information see below: 

http://www.massbio.org/events/calendar/2496-from_academia_to_industry_part_ii_using_animal/event_detail

ATR Founder Masha Fridkis-Hareli has been invited to present a workshop for international students at the National Symposium for Advancement of Women in STEM (NSAWS) held at the Harvard University in Cambridge, MA. NSAWS is a national conference for college women in STEM organized by Women in Science at Harvard-Radcliffe. For more information see: http://www.nsawswishr.org/speakers.html

ATR Founder and President Masha Fridkis-Hareli was interviewed on women scientist’s career issues for the Showdown section of the AWIS magazine. For details see the link below: http://magazine.awis.org/i/442013-winter-2014/25

ATR Founder Masha Fridkis-Hareli organized and moderated a Mass Bio forum titled: From Academia to Industry Part I: Using Animal Models in Pre-Clinical Drug Development. This is the first of a two part Forum where academic investigators discuss applications of their research animal models for collaborative initiatives with biotechnology industry aiming at accelerating translation of early stage candidates into drug discovery and development programs. For more information see below: http://www.massbio.org/events/calendar/2383-from_academia_to_industry_part_i_using_animal/event_detail

ATR Founder Masha Fridkis-Hareli presented a webinar titled: Developing a Mentoring Program: Lessons from Experience. Strong mentoring relationships are one of the few, proven techniques for increasing career success. AWIS Massachussettschapter has been running MASS-AWIS Mentoring Circle Program successfully for five years. This program has been providing women scientists in the Boston area with the opportunity to realize the benefits of group mentoring. For more information see below: http://www.awis.org/event/id/385922/AWIS-Webinar-Developing-a-Mentoring-Program-Lessons-from-Experience.htm

ATR Founder Masha Fridkis-Hareli has been nominated a co-Chair of the Drug Discovery Working Group at the Massachusetts Biotechnology Council (Mass Bio). The Drug Discovery Working Group is one of 9 new groups tasked with developing new content as well as shaping and executing programs at Mass Bio. For more information see below: http://www.bizjournals.com/boston/blog/bioflash/2013/05/massbio-taps-life-science-execs-to.html?page=all

ATR Founder Masha Fridkis-Hareli was invited to the Drug Discovery Forum at MassBio to present a seminar titled: Novel Amino Acid Copolymers for Treatment of Autoimmune Diseases. This presentation highlights Dr. Hareli’s post-doctoral work at the Harvard University where she designed and developed a group of novel compounds for treatment of autoimmune diseases currently in Phase II clinical trials. For more information see below: http://www.massbio.org/events/calendar/1937-amino_acid_copolymers_therapeutic_promise_for/event_detail

ATR Founder Masha Fridkis-Hareli was invited by the Office of the Vice President for Research at MIT to present a seminar on transition from academia to industry. This is an interactive presentation that explores career opportunities outside academia. Based on her personal experiences in academia and industry, Dr. Hareli discusses differences between these two sectors and describes the skill set needed to make this transition smooth and enjoyable. Her presentation is best fitted to graduate and post-doctoral scientists who are considering transitioning to industry but have no insider view of the process. For more information see below: https://postdocs.mit.edu/career-development/presentation-notes-and-videos/career-exploration-academic-and-non-academic-2

ATR Founder Masha Fridkis-Hareli presented at the Networking Night: Entrepreneurs and the Businesses They Created, held at the Harvard University. This event focuses on Ph.D. entrepreneurs and the businesses they have created. The entrepreneurs hold doctorates in Design and Computation, Mechanical Engineering, Molecular Biology, Virology, Immunology, and Biochemistry. The Networking Nights events are an opportunity for postdocs to learn first-hand information about the career paths and current fields of these representatives in a casual, intimate and social environment. For more information see below: http://www.lunascientificstorytelling.com/?page_id=22

ATR Founder Masha Fridkis-Hareli participated as a panelist in the CRO/CMO 2nd Annual Accelerating Drug Development Symposium held in Newton, MA. The Massachusetts CRO/CMO Symposium is designed to bring together the biopharmaceutical industry and the Massachusetts CRO/CMO cluster. The event showcases the roles these types of partnerships are playing in accelerating drug development. For more information see: http://www.massbio.org/events/calendar/1764-ma_cro_cmo_symposium/event_detail/452